Tag: Gene-Editing Transfection Chemicals Market Share

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Gene-Editing Transfection Chemicals Market Over The Five-Year Period 2025–2029?

The gene-editing transfection chemicals market has seen substantial growth recently. It is forecast to expand from $0.99 billion in 2024 to $1.07 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.0%. The growth observed in the past can be attributed to the early adoption of CRISPR-Cas9 systems, growing focus on cancer and genetic disorder research, initial demand from academic and research institutions, availability of basic chemical transfection reagents, and the rapid rise of cell biology and molecular diagnostics.

The gene-editing transfection chemicals market is projected to experience robust expansion over the coming years. This market is forecast to reach $1.45 billion by 2029, achieving a compound annual growth rate (CAGR) of 7.8%. Several factors are expected to drive this growth during the forecast period, including the increased application of gene editing in clinical treatments, a rise in investments within the biotechnology and pharmaceutical sectors, an escalating need for non-viral delivery methods, the increasing occurrence of rare and inherited conditions, a worldwide focus on personalized medicine, and an increase in regenerative therapies. Key trends anticipated during the forecast period involve a move towards nanoparticle and lipid-based delivery mechanisms, the embrace of automation and high-throughput platforms, the development of microfluidic and single-cell delivery technologies, the incorporation of nanotechnology, and the use of core-shell silica nanoparticle systems.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25770&type=smp

Which Industry Drivers Are Expected To Accelerate The Gene-Editing Transfection Chemicals Market From 2025 To 2029?

The gene-editing transfection chemicals market is expected to expand moving forward, propelled by the rapid advancements in gene therapy research. Gene therapy is a method focused on treating or preventing illnesses by directly altering or repairing faulty genes within a patient’s cells. The acceleration in gene therapy research is attributed to breakthroughs in gene-editing technologies like CRISPR, which allow scientists to accurately target and modify genes responsible for genetic disorders. Gene-editing transfection chemicals are indispensable tools in gene therapy research and development, as they enable the effective delivery of genetic material, such as CRISPR-Cas9 components, mRNA, and plasmid DNA, into human cells. For instance, according to PartnerRe, a Switzerland-based insurance company, in August 2024, the FDA had approved 7 gene therapies by the end of 2023, and 2024 is on track to establish a new record with seven additional approvals in just the first half of the year. Currently, more than 500 gene therapies are under development, and the FDA anticipates approving another 10 to 20 gene and cell therapies by 2025. Consequently, the intensified research in gene therapy is driving the growth of the gene-editing transfection chemicals market.

What Are The Segment Types Shaping The Gene-Editing Transfection Chemicals Market?

The gene-editing transfection chemicals market covered in this report is segmented –

1) By Chemical Type: Lipid-Based, Polymer-Based, Peptide-Based, Other Chemical Types

2) By Delivery Mechanism: Non-Viral, Viral

3) By Application: Biomedical Research, Drug Discovery, Disease Modeling, Agricultural Biotechnology, Vaccine Development, Other Applications

4) By End-User: Academic And Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Lipid-Based: Cationic Lipids, Neutral Lipids, Ionizable Lipids

2) By Polymer-Based: Polyethyleneimine (PEI), Poly(L-Lysine) (PLL), Dendrimers

3) By Peptide-Based: Cell-Penetrating Peptides (CPPs), Amphipathic Peptides, Targeting Peptides

4) By Other Chemical Types: Inorganic Nanoparticles, Hybrid Nanoparticles

What Are The Latest Industry Trends Transforming The Gene-Editing Transfection Chemicals Market?

Major companies in the gene-editing transfection chemicals market are focusing on introducing innovative solutions, such as lipid nanoparticle (LNP) starter kits, to streamline gene therapy and mRNA delivery workflows. Lipid nanoparticle (LNP) starter kits are ready-to-use formulations or toolkits that include pre-optimized lipid components and protocols designed to facilitate the development and testing of LNP-based delivery systems. For instance, in February 2024, CordenPharma, a Switzerland-based pharmaceutical company, launched Lipid NanoParticle (LNP) Starter Kits, intended to support researchers and developers in formulating and optimizing mRNA-based therapeutics, including vaccines and gene therapies. These kits contain four key lipids, such as ionizable lipids, helper lipids, sterols, and PEGylated lipids, obtained from commercial-scale, high-purity materials to ensure batch-to-batch consistency and reduce the risk of losing valuable payloads during development. By offering a reliable and scalable lipid platform, CordenPharma aims to accelerate the gene editing and mRNA therapeutic development process while safeguarding high-value genetic payloads.

Which Industry Leaders Are Driving Innovation Across The Gene-Editing Transfection Chemicals Market?

Major companies operating in the gene-editing transfection chemicals market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, Integrated DNA Technologies Inc., Promega Corporation, Eurogentec S.A., Horizon Discovery Group plc, OriGene Technologies Inc., Enzo Life Sciences Inc., Apollo Scientific Ltd., Mirus Bio LLC, OZ Biosciences SAS, Genlantis Inc., Polyplus-Transfection SA, Altogen Biosystems LLC, Canvax Biotech S.L., EZ Biosystems LLC, SignaGen Laboratories.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gene-editing-transfection-chemicals-global-market-report

Which Region Currently Holds The Largest Share Of The Gene-Editing Transfection Chemicals Market?

North America was the largest region in the gene-editing transfection chemicals market in 2024. The regions covered in the gene-editing transfection chemicals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gene-Editing Transfection Chemicals Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25770&type=smp

Browse Through More Reports Similar to the Global Gene-Editing Transfection Chemicals Market 2025, By The Business Research Company

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Crispr Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Genome Editing Or Genome Engineering Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Gene-Editing Transfection Chemicals Industry By 2029?

The market size for gene-editing transfection chemicals has seen robust growth in the past few years. The market value is projected to increase from $0.99 billion in 2024 to $1.07 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. The increase during the historic period is linked to the early use of CRISPR-Cas9 systems and a rising focus on cancer and genetic disorder research. Other contributing factors include initial demand from academic and research entities, availability of rudimentary chemical transfection reagents, and the swift advancement of cell biology and molecular diagnostics.

The market for gene-editing transfection chemicals is set to experience substantial growth in the coming years, reaching a total value of $1.45 billion in 2029, indicative of a compound annual growth rate (CAGR) of 7.8%. Several factors are driving this growth during the forecast period, such as the increasing application of gene editing in clinical treatments, the broadening investments in biotechnology and pharmaceuticals, the surging demand for non-viral delivery systems, a rising incidence of rare and inherited disorders, a worldwide focus on personalized medicine, and an increase in regenerative treatments. Notable trends anticipated during this period encompass a move towards nanoparticle and lipid-based delivery, increased adoption of automation and high-throughput platforms, the appearance of microfluidic and single-cell delivery systems, the incorporation of nanotechnology, and the development of core-shell silica nanoparticle systems.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25770&type=smp

Which Factors Are Steering Growth In The Gene-Editing Transfection Chemicals Market?

The advancement of gene therapy research is predicted to stimulate the expansion of the gene-editing transfection chemicals market. Gene therapy, a method that aims to cure or avert diseases by directly altering or rectifying faulty genes within an individual’s cells, is seeing rapid research developments driven by advancements in gene-editing technologies like CRISPR. This enables scientists to accurately target and amend defective genes causing genetic disorders. The essential role of gene-editing transfection chemicals is in gene therapy research and development, facilitating the effective delivery of genetic components such as CRISPR-Cas9, mRNA and plasmid DNA into human cells. As an illustration, in August 2024, PartnerRe, an insurance company based in Switzerland, stated that by the close of 2023, the FDA had endorsed 7 gene therapies, and 2024 is on set to establish a new record with an additional seven approvals in just the first half of the year. At present, over 500 gene therapies are under development, and it is anticipated that the FDA will approve an extra 10 to 20 gene and cell therapies by 2025. Hence, the rapid development in gene therapy research is fueling the expansion of the gene-editing transfection chemicals market.

Which Segment Accounts For The Largest Share In The Gene-Editing Transfection Chemicals Market?

The gene-editing transfection chemicals market covered in this report is segmented –

1) By Chemical Type: Lipid-Based, Polymer-Based, Peptide-Based, Other Chemical Types

2) By Delivery Mechanism: Non-Viral, Viral

3) By Application: Biomedical Research, Drug Discovery, Disease Modeling, Agricultural Biotechnology, Vaccine Development, Other Applications

4) By End-User: Academic And Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Lipid-Based: Cationic Lipids, Neutral Lipids, Ionizable Lipids

2) By Polymer-Based: Polyethyleneimine (PEI), Poly(L-Lysine) (PLL), Dendrimers

3) By Peptide-Based: Cell-Penetrating Peptides (CPPs), Amphipathic Peptides, Targeting Peptides

4) By Other Chemical Types: Inorganic Nanoparticles, Hybrid Nanoparticles

Which Long-Term Trends Will Play A Crucial Role In The Gene-Editing Transfection Chemicals Market?

Presenting innovative solutions, like lipid nanoparticle (LNP) starter kits, is becoming a focus for key players in the gene-editing transfection chemicals market. These are intended to simplify the workflows of gene therapy and mRNA delivery. LNP starter kits are essentially ready-made formulations or toolkits, each including pre-optimised lipid components and associated procedures for easier development and testing of LNP-based delivery mechanisms. For instance, in February 2024, CordenPharma, a pharmaceutical firm based in Switzerland, introduced their Lipid NanoParticle (LNP) Starter Kits. These kits are specifically designed to assist researchers and developers in creating and finetuning mRNA-based therapeutics like vaccines and gene therapies. Each kit includes four main lipids – ionizable lipids, helper lipids, sterols, and PEGylated lipids. These were taken from commercial-scale, ultra-pure materials to guarantee constant batch-to-batch quality and limit the chance of losing valuable payloads throughout the development process. CordenPharma’s purpose in offering a trustworthy and scalable lipid platform is to hasten the process of gene editing and mRNA therapeutic development and to protect highly valuable genetic payloads.

Who Are The Dominant Players In The Gene-Editing Transfection Chemicals Market Today?

Major companies operating in the gene-editing transfection chemicals market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, Integrated DNA Technologies Inc., Promega Corporation, Eurogentec S.A., Horizon Discovery Group plc, OriGene Technologies Inc., Enzo Life Sciences Inc., Apollo Scientific Ltd., Mirus Bio LLC, OZ Biosciences SAS, Genlantis Inc., Polyplus-Transfection SA, Altogen Biosystems LLC, Canvax Biotech S.L., EZ Biosystems LLC, SignaGen Laboratories.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gene-editing-transfection-chemicals-global-market-report

What Regional Factors Are Accelerating Growth In The Gene-Editing Transfection Chemicals Market?

North America was the largest region in the gene-editing transfection chemicals market in 2024. The regions covered in the gene-editing transfection chemicals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25770&type=smp

Browse Through More Reports Similar to the Global Gene-Editing Transfection Chemicals Market 2025, By The Business Research Company

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Gene Synthesis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-synthesis-global-market-report

Nucleic Acid Based Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Gene-Editing Transfection Chemicals Market From 2025 to 2029?

The size of the gene-editing transfection chemicals market has seen significant growth in recent times. It is set to expand from $0.99 billion in 2024 to $1.07 billion in 2025, recording a compound annual growth rate (CAGR) of 8.0%. The historical growth can be ascribed to early implementation of CRISPR-Cas9 systems, increased concentration on research about cancer and genetic disorders, preliminary demand stemming from academic and research bodies, access to elementary chemical transfection reagents, along with the swift expansion of cell biology and molecular diagnostics.

Over the coming years, the market size for gene-editing transfection chemicals is predicted to experience substantial growth, expanding to $1.45 billion in 2029 with a compound annual growth rate (CAGR) of 7.8%. This anticipated growth in the forecast period is ascribed to numerous factors such as the heightened application of gene editing in clinical therapies, increased investment in the biotech and pharma sectors, a surge in demand for non-viral delivery systems, a rise in occurrences of rare and inherited diseases, a global advancement towards personalized medicine, and the growing landscape of regenerative treatments. Key trends for the forecast period include a transition towards nanoparticle and lipid-based delivery, the implementation of automation and high-throughput platforms, the introduction of microfluidic and single-cell delivery systems, the incorporation of nanotechnology, and the evolution of core-shell silica nanoparticle systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25770&type=smp

What Elements Are Contributing To Growth In The Gene-Editing Transfection Chemicals Market?

The swift progression in gene therapy research is anticipated to drive the expansion of the gene-editing transfection chemicals market. Gene therapy, a method that endeavors to cure or avert diseases by directly amending or rectifying malformed genes within an individual’s cells, is currently experiencing a boost. This is thanks to advances in gene-editing technologies like CRISPR, which facilitates scientists to accurately pinpoint and modify defective genes accountable for genetic disorders. Gene-editing transfection chemicals, which serve as critical instruments in gene therapy research and development, empower the effectual delivery of genetic elements like CRISPR-Cas9 components, mRNA, and plasmid DNA into human cells. For example, as reported by PartnerRe, a Switzerland-based insurance firm, by the close of 2023, the FDA endorsed 7 gene therapies, and 2024 is set to establish a new milestone with an additional seven approvals in the first half of the year alone. Presently, over 500 gene therapies are under development, and between 10 to 20 more gene and cell therapies are projected to gain FDA approval by 2025. As such, the swift advancement in gene therapy research is fueling the expansion of the gene-editing transfection chemicals market.

Which Segments Are Detailed In The Global Gene-Editing Transfection Chemicals Market Report?

The gene-editing transfection chemicals market covered in this report is segmented –

1) By Chemical Type: Lipid-Based, Polymer-Based, Peptide-Based, Other Chemical Types

2) By Delivery Mechanism: Non-Viral, Viral

3) By Application: Biomedical Research, Drug Discovery, Disease Modeling, Agricultural Biotechnology, Vaccine Development, Other Applications

4) By End-User: Academic And Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Lipid-Based: Cationic Lipids, Neutral Lipids, Ionizable Lipids

2) By Polymer-Based: Polyethyleneimine (PEI), Poly(L-Lysine) (PLL), Dendrimers

3) By Peptide-Based: Cell-Penetrating Peptides (CPPs), Amphipathic Peptides, Targeting Peptides

4) By Other Chemical Types: Inorganic Nanoparticles, Hybrid Nanoparticles

Which Emerging Trends And Strategic Shifts Are Shaping The Gene-Editing Transfection Chemicals Market?

Companies in the forefront of the gene-editing transfection chemicals market are geared towards launching cutting-edge solutions like lipid nanoparticle (LNP) starter kits to simplify gene therapy and mRNA delivery processes. The lipid nanoparticle (LNP) starter kits come as pre-packed formulations or comprehensive toolkits packed with optimised lipid elements and procedures constructed to ease the creation and evaluation of LNP-driven delivery systems. For instance, in February 2024, CordenPharma, a pharmaceutical firm based in Switzerland, rolled out Lipid NanoParticle (LNP) Starter Kits. The primary purpose of these kits is to assist researchers and video game developers in formulating and improving mRNA-based treatments, such as vaccines and gene therapies. The kits comprise four main lipids like ionisable lipids, helper lipids, sterols, and PEGylated lipids. These have been sourced from commercial-scale, high-purity materials to ascertain consistency between batches and minimise potential loss of high valued payloads during the developmental stages. By introducing a dependable, scalable lipid platform, CordenPharma is committed to expediting gene-editing and mRNA therapeutic development, whilst protecting high-value genetic payloads.

Who Are The Key Contributors To Growth In The Gene-Editing Transfection Chemicals Market?

Major companies operating in the gene-editing transfection chemicals market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, Integrated DNA Technologies Inc., Promega Corporation, Eurogentec S.A., Horizon Discovery Group plc, OriGene Technologies Inc., Enzo Life Sciences Inc., Apollo Scientific Ltd., Mirus Bio LLC, OZ Biosciences SAS, Genlantis Inc., Polyplus-Transfection SA, Altogen Biosystems LLC, Canvax Biotech S.L., EZ Biosystems LLC, SignaGen Laboratories.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gene-editing-transfection-chemicals-global-market-report

Which Region Is Projected To Lead The Gene-Editing Transfection Chemicals Market By 2025?

North America was the largest region in the gene-editing transfection chemicals market in 2024. The regions covered in the gene-editing transfection chemicals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25770&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model